ACADEMIC POSITIONS
2000-present: For six years Director of Studies, then for two years Research Fellow, then Lecturer in Economics, Oriel College, University of Oxford.
2015-present: Teaching Fellow, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford.
2017-present: Visiting Professor, Institute of Drugs Technology, Oswaldo Cruz Foundation, Brazil.
2018-2022: Head of Global Health Initiatives, Oxford in Berlin, Co-Chair Global Health Strategy Group for Pandemic Lessons and Future Pandemic Preparedness.
2010-2022: Fellow, and Senior Fellow, Oxford Martin School, University of Oxford.
2013-2017: Co-PI, International Research Consortium on Dengue Risk Assessment, Management and Surveillance (EU-funded).
2011-2017: Senior Research Fellow, Department of Zoology (Spatial Ecology and Epidemiology Group), University of Oxford.
2010-2015: Co-PI, Oxford Martin Programme on Vaccines, Oxford Martin School, and Jenner Institute, University of Oxford.
2006-2008: Senior Research Fellow, Saïd Business School, University of Oxford.
2006-2008: Research Fellow, James Martin Institute for Science and Civilisation.
OTHER ACADEMIC RESPONSIBILITIES
2024-present: Appointed Oxford Global Health representative at the European Global Health Research Institutes Network (EGHRIN).
2024-present: Social Science lead, Oxford AMR Network.
2022-present: Chair, Global Health Policy Partnership (University of Oxford and global partners)
2015-present: Lecturer, MSc in International Health & Tropical Medicine, University of Oxford, and MSc in Public Health and Policy, University of Oxford. Co-lead Vaccinology module.
2007-present: MSc, MPhil, and DPhil theses supervisor and examiner, University of Oxford.
2004-present: Lecturer MSc Global Health Science, University of Oxford. Also, advising students in the Global Health Science MSc, MBA, and MPP, and other students on a wide variety of projects with a global health angle.
2000-present: Lecturing in Macroeconomics for Final Examinations, Money and Banking for Final Examinations, University of Oxford.
2015-2018: Lecturer, Theoretical Epidemiology & Public Health course, Department of Zoology, University of Oxford.
2007-2009: Economics exam moderator, Department of Economics, University of Oxford, for Philosophy, Politics & Economics, and History & Economics.
1994-1996: Research Officer, Institute of Economics and Statistics, University of Oxford.
1985-1988: Belfast, Northern Ireland: Coordinator of inner-city economic and community development projects.
CURRENT PROFESSIONAL EXPERIENCE
2020-present: Co-Chair, Supply and Market Dynamics and Medicine Quality Working group, of the Covid-19 Clinical Research Coalition, now CERCLE, the ‘Coalition for Equitable Research in Low-Resource Settings’.
2023-present: Guest Editor, Vaccines special issue ‘The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs’
2022-present: Chair, Working Group for Collaborations and Outreach (including digital and AI for health Challenges) of the ITU-WHO Focus Group on Artificial Intelligence for Health (FG-AI4H), ow ‘Global Initiative on AI for Health’ (WHO, ITU, WIPO).
2021-present: Member, Global Health Strategy Group for Digital Health and AI for Health.
2021-present: Member, Global Health Strategy Group for Antimicrobial Resistance.
2020-present: Founder and Chair, Global Partnership for Biodiversity, Medicine, and Health.
2009-present: Member, UK Joint Committee on Vaccination and Immunisation (JCVI), Subcommittee on Varicella Zoster.
PREVIOUS PROFESSIONAL EXPERIENCE
– Consultant, SECURE initiative for access to antibiotics, GARDP/WHO.
– Expert testimony on evaluation framework, evaluation criteria, and inventory of financing proposals of the EWG, WHO Expert Working Group on R&D Financing.
– Chair and Lead Economist (in charge of the scoping/planning activity), Task Force on Economics and Product Profiles of the Stop TB Working Group on New Vaccines (Aeras, Bill and Melinda Gates Foundation, and WHO).
– Member, WHO Neglected Tropical Diseases Investment for Impact Working Group.
– Advisor, The X PRIZE Foundation, on the design of a prize for effective diagnosis of tuberculosis in LMICs.
– Research grant peer reviewer, Economic and Social Research Council.
– Research grant peer reviewer, National Institute for Health Research.
– Research grant peer reviewer, British Council.
– Co-organiser, Oxford Conference on Innovation and Technology Transfer for Global Health (with financial support of the Bill and Melinda Gates Foundation).
– Consultant, Pharmaceutical R&D Policy Project, London School of Economics, and the Health Policy Division of the George Institute for International Health, Australia (providing help with developing modelling tools, especially portfolio analysis of malaria drugs and vaccines, and thoughts on the G-Finder process, both financially supported by the Bill and Melinda Gates Foundation).
– Academic referee, Economic Journal.
– Academic referee, Health Policy and Planning.
– Academic referee, Oxford Review of Economic Policy.
– Academic referee, The Lancet.
– Academic referee, Economic and Social Research Council.
– Academic referee, World Bank.
– Academic referee, PL0S Medicine.
– Academic referee, Routledge.
– Academic referee, Oxford University Press.
– Academic referee, PLOS Neglected Tropical Diseases.
– Academic referee, American Journal of Public Health.
– Advisor, Aeras TB Vaccine Foundation and Bill and Melinda Gates Foundation: advice on investment case for the biggest grant thus far ($200m) made by the Bill and Melinda Gates Foundation to a Product Development Partnership.
– Advisor, Bill and Melinda Gates Foundation and Pediatric Dengue Vaccine Initiative: advice on, and reform of, PDP model being used for development of dengue vaccines.
– Advisor, TB Alliance: Valuation of TB drugs portfolio and funding needs.
– Advisor, various government ministries and WHO representatives, including of: Italy; Holland; Germany; Korea; Brazil; New Zealand; Thailand; Malaysia; and US.
– Consultant and expert Witness, South African Competition Commission, Consumer Project on Technology, and Rockefeller Foundation: advice on submission to the South African Competition Commission on the pricing of AIDS drugs in South Africa.Results for Development Institute: independent analysis for a three-year project funded by the Bill and Melinda Gates Foundation titled ‘Assessing Innovations in Global Health R&D Policy and Financing’.
– Advisor, economics of global health and R&D for: WHO; UNDP; World Bank; DFID; UK Treasury; Médecins Sans Frontières Campaign for Access to Essential Medicines; NDG; Global Alliance for Vaccines and Immunization; Oxfam; Wellcome Trust; Action Aid; WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH); Office of Health Economics, London; German Bundestag.
– Advisor, Dalberg, Global Development Advisors, into funding mechanisms and R&D incentives for malaria (funded by the Bill and Melinda Gates Foundation); academic contributor to work on extensions of the principle of the ‘Affordable Medicines Facility for malaria’ (the financing mechanism to subsidize malaria ACTs globally implemented by the Global Fund) to other development topics inside and outside of global health; advice on Fund for R&D in Neglected Diseases (FRIND).
– Advisor, biotechnology and vaccine companies (e.g., GSK Biologicals, Hawaii Biotech, InViragen, Oxitec, Sanofi Pasteur, Merck) and investment banks (e.g., Credit Suisse First Boston, Goldman Sachs) and not-for-profits on strategic issues especially relating to neglected diseases.
– Writer and consultant, Oxford Analytica: financial bubbles and emerging market risks; banking; the US economy; fiscal crises.
– Writer and consultant, Credit Suisse First Boston: UK house prices, financial bubbles.
– Consultant, The World Economic Forum, Global Health Initiative, ‘Tackling Tuberculosis: The Business Response’: Report reviewer.
– Advisor, The Rockefeller Foundation, The Ford Foundation, United Nations Development Program, and the Carnegie Council on Ethics and International Affairs (international trade, Intellectual Property, including TRIPS, access to medicines, public health, and alternative finance for health R&D).